Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) ROCE % : 9.70% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Laboratorio Farmaceutico Erfo SpA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Laboratorio Farmaceutico Erfo SpA's annualized ROCE % for the quarter that ended in Jun. 2024 was 9.70%.

Laboratorio Farmaceutico Erfo SpA ROCE % Historical Data

The historical data trend for Laboratorio Farmaceutico Erfo SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorio Farmaceutico Erfo SpA ROCE % Chart

Laboratorio Farmaceutico Erfo SpA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

50.92

29.22

25.69

14.00

9.41

Laboratorio Farmaceutico Erfo SpA Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial				19.57	7.30	15.37	3.96	9.70

Laboratorio Farmaceutico Erfo SpA ROCE % Calculation

Laboratorio Farmaceutico Erfo SpA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	0.845	/	( ( (10.534 - 2.056)	+	(10.146 - 0.665) )	/ 2 )
	=	0.845	/	( (8.478	+	9.481)	/ 2 )
	=	0.845	/	8.9795
	=	9.41 %

Laboratorio Farmaceutico Erfo SpA's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	0.85	/	( ( (10.146 - 0.665)	+	(10.521 - 2.476) )	/ 2 )
	=	0.85	/	( ( 9.481	+	8.045 )	/ 2 )
	=	0.85	/	8.763
	=	9.70 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Laboratorio Farmaceutico Erfo SpA ROCE % Related Terms

Thank you for viewing the detailed overview of Laboratorio Farmaceutico Erfo SpA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorio Farmaceutico Erfo SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RK7:Germany

Address

Viale Geki Russo Lo. Pontegallo, Villafranca Tirrena, Messina, ITA, 98049

Website

https://www.erfo.it

Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.

Laboratorio Farmaceutico Erfo SpA Headlines

No Headlines